Standard BioTools ( (LAB) ) has issued an announcement.
Standard BioTools Inc. reported a third-quarter 2024 revenue of $45 million, highlighting a 50% improvement in adjusted EBITDA and a 35% reduction in net loss year-over-year. The company operationalized $80 million in merger synergies, aiming for adjusted EBITDA break-even by 2026. With a strong balance sheet, they are focusing on commercial execution and investing in growth within their multi-omics portfolio, while also pursuing strategic mergers and acquisitions to solidify their position in the life science tools industry.
Learn more about LAB stock on TipRanks’ Stock Analysis page.
